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The accompanying research report by King and colleagues [1]
describes a trachoma survey performed in Ayod County, southern
Sudan. They performed a cross-sectional two-stage cluster survey
of trachoma status in November 2006 and found levels of disease
that rival those in the most hyper-endemic areas: 88% of children
between ages 1 and 9 years had clinically active trachoma and the
children were actually starting to show trichiasis (approximately
3%). In those over 14 years of age, 59% had clinically active
trachoma, 14.6% had trichiasis, and 6.4% had corneal opacity.
Trachoma was present in virtually all households; 98% had at least
one person having active trachoma, and one-third of households
had individuals with trichiasis.
Although a number of conditions generally considered to be risk
factors for trachoma were commonly found (for example, only 5%
of households had latrines and water availability was limited, with
journey times to fetch water of more than 30 minutes), these alone
could not account for the severity of the disease the authors
described. What is certain is that in this extremely impoverished
area of Sudan, blinding trachoma is a major public health problem.
There has been a major collapse of infrastructure, and rudimentary
public health measures have been lacking for many years.
However, when faced with reports of such high levels of disease,
one must be highly sensitive to the possibility of systematic bias in
the clinical grading. The World Health Organization scheme used
here has proven invaluable for trachoma programs to assess which
areas will require mass (community-wide) treatment. However, the
grading scale is subjective, imprecise, and not a particularly good
indicator for infection with the ocular strains of chlamydia that
cause trachoma. It was developed for, and is best used within
programs, but does not have the fine distinctions in grading
clinical disease that one would like to see within scientific reports.
King et al. report data from within a trachoma elimination
program. They have undertaken evaluations and statistical
analyses to ensure that the clinical scoring generated by their
field workers was consistent and agreed with a standardized set of
photos. However, these field workers were relatively inexperienced
at dealing with trachoma and were specially trained for this
program. The data they have generated will be valuable in the
monitoring and evaluation of their trachoma elimination program.
There are good self-serving reasons for those performing surveys
in the context of control programs to provide the most solid
evidence of the validity of their baseline findings. Systematic
overscoring of clinical disease at baseline will almost certainly
result in a successful outcome for any intervention; it could make
the results of ineffective programs appear good, and the results of
good programs appear spectacular. It is far better to provide
evidence for the baseline levels that either cannot be questioned, or
which can be validated. Thus, the unbiased reader would really
like to have something besides subjective clinical classifications.
A relatively easy way to document the validity of the clinical
classifications is to take photographs of the conjunctivae and make
these available for external review to ensure that there is no over-
grading. Digital photography now offers the ability to generate
high-quality records of the initial clinical findings for validation
purposes. It is not clear to us why photography is not a routine tool
used by programs to monitor their success. A further option would
be to document Chlamydia trachomatis infection using current
generation nucleic acid amplification tests (NAATs) to detect the
causative agent of trachoma. While this may not be the current
state-of-the-art for trachoma surveys, and has cost implications, it
has proved a useful tool for documenting prevalence rates of
chlamydial infection in trachoma-endemic areas, and the positivity
prior to treatment correlates well with disease intensity [2]. To
reduce costs, a sampling strategy could be developed to use NAAT
testing before the program is implemented to estimate a baseline
prevalence of infection, and to compare this to results obtained
after implementation of the AFE aspects of the Surgery,
Antibiotics, Facial hygiene and Environmental improvements
(SAFE) strategy [3]. The lower prevalence of infection seen after
treatment allows specimen pooling strategies to further reduce
costs of NAAT testing. Infection is a more sensitive indicator of the
success of antibiotic treatment than is clinical disease, which takes
a longer time to resolve. Perhaps resources for NAAT testing were
not available, and there were concerns about the use of swabs, and
transport of specimens to the laboratory; but certainly in the era of
digital photography it is not unreasonable to request documenta-
tion of clinical findings for such a report.
Having raised this caveat, we must congratulate King and
colleagues for performing this survey under extraordinarily
difficult conditions. They are working in an area where supplies
are difficult to obtain, and where there is civil unrest. They have
documented an extremely high prevalence of clinically active
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trachoma and blinding and pre-blinding lesions that indicate that
attention will have to be paid to the trachoma problem in this area
for decades to come, as the lesions progress. Certainly, there are
other trachoma-endemic areas that are impoverished and where
infrastructure collapse will have created an environment that
allows trachoma to flourish to levels similar to those seen here.
Indeed, studies in the past several years in Ethiopia have also
found alarming rates of active disease and trichiasis, indicating an
unprecedented need for corrective lid surgery. The work of King
and colleagues will bring deserved attention to this problem.
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